DEFA14A: Biotech Firm Adjourns Shareholder Meeting, Sets 1-for-15 Reverse Split to Boost Stock and Fund Trials

A clinical-stage biotechnology company has adjourned its annual general meeting to July 14, 2025, and set a 1-for-15 reverse share split ratio to regain Nasdaq listing compliance and facilitate future capital raising.

Summary

• The 2025 Annual General Meeting (AGM), originally scheduled for July 7, 2025, was convened and immediately adjourned for one week, now set to reconvene on July 14, 2025, at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time.
• The reconvened meeting will be held at the offices of Meitar Law Offices in Ramat Gan, Israel, with options for attendance via live webcast or phone.
• The Board of Directors has set the proposed reverse share split ratio at 1-for-15, which would increase the par value of ordinary shares to $0.135 per share.
• This reverse share split is intended to maximize the increase in the market price of ordinary shares to assist in raising capital for activities and clinical trials for the siRNA product candidate, SIL204.
• The split is also expected to restore compliance with Nasdaq Listing Rules 5450(a)(1) and/or 5550(a)(2), which require a minimum bid price of $1.00 per share.
• The 1-for-15 ratio will ensure the number of publicly held shares remains above 500,000, the minimum for continued listing on the Nasdaq Capital Market, to which the company seeks to transfer its listing.
• Proposals for the AGM include the re-election of seven directors, the re-appointment of Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) as independent public accountants for the year ending December 31, 2025, and the additional period until the next annual general meeting.
• Other proposals include the approval of the reverse share split (Proposal 3) and an increase of 1,271,859 ordinary shares (to a total of 1,428,268 ordinary shares, adjusted proportionately for the split) reserved for issuance under the 2024 Equity Incentive Plan (Proposal 4).
• The record date for the Annual Meeting remains the close of business on June 24, 2025.

Sentiment

Score: 3

Explanation: While the company is taking proactive steps to address Nasdaq listing compliance and secure future funding, the necessity of a reverse share split and explicit mention of capital raising needs indicate underlying financial challenges and a low stock price.

Positives

• Proactive steps are being taken to address Nasdaq listing compliance issues and maintain market presence.
• The setting of a specific reverse share split ratio (1-for-15) provides clarity and a defined path forward for shareholders.
• The reverse split is strategically aimed at facilitating future capital raising, which is critical for funding ongoing activities and advancing clinical trials for the siRNA product candidate, SIL204.
• The company's first-generation product, LODER, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer.
• Advancing the next-generation siRNA candidate, SIL204, which has shown significant potential in preclinical studies, indicates continued pipeline development.

Negatives

• The necessity of a reverse share split indicates the company's ordinary shares are currently trading below Nasdaq's minimum bid price requirement of $1.00, signaling a challenge in market valuation or investor confidence.
• The explicit mention that the reverse split will assist in raising capital suggests a current need for additional funding to support operations and clinical trials.
• The adjournment of the Annual General Meeting, while allowing for shareholder consideration, could be perceived as a delay in critical corporate actions.

Risks

• Ability to maintain Nasdaq listing and restore compliance with all Nasdaq Listing Rules.
• Future capital requirements and the ability to obtain additional capital.
• Impact of the regulatory environment and compliance complexities.
• Silexion's strategy, future operations, financial position, projected costs, prospects, and plans.
• Other risks and uncertainties set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company aims to restore compliance with Nasdaq Listing Rules 5450(a)(1) and/or 5550(a)(2) by maintaining a minimum bid price of $1.00 per share through a proposed 1-for-15 reverse share split. This action is also intended to maximize the increase in market price to assist in raising capital to support its activities and clinical trials for its siRNA product candidate, SIL204. The company seeks to transfer its listing to the Nasdaq Capital Market and maintain at least 500,000 publicly held shares.

Industry Context

The need for a reverse stock split to maintain Nasdaq listing is a common occurrence for smaller, clinical-stage biotechnology companies that may experience prolonged periods of low stock prices due to the long development cycles, high R&D costs, and lack of immediate revenue. The company's focus on RNA interference (RNAi) therapies for KRAS mutations aligns with a growing trend in oncology towards targeted therapies and gene-editing technologies, which are areas of significant investment and research within the broader pharmaceutical and biotech industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a 1-for-15 reduction in the number of shares held, with a proportional increase in share price and par value, if the reverse split is approved. This is intended to prevent delisting and enable future capital raises, which could be beneficial long-term but signals current share price weakness.
• Employees: The increase in shares reserved for the equity incentive plan could provide more opportunities for stock-based compensation, potentially improving retention and motivation.
• Creditors: Maintaining Nasdaq listing and the ability to raise capital could improve the company's financial stability, potentially reducing credit risk.
• Customers/Patients: Successful capital raising and continued clinical trials for SIL204 and LODER could lead to new or improved therapies for difficult-to-treat cancers.

Next Steps

• Reconvened Annual General Meeting on July 14, 2025, to vote on proposals including director re-election, auditor re-appointment, reverse share split, and equity incentive plan share increase.
• Shareholders who have not submitted or wish to change their proxy are urged to do so promptly before the reconvened meeting.
• Potential implementation of the 1-for-15 reverse share split if approved by shareholders.
• Efforts to restore compliance with Nasdaq Listing Rules 5450(a)(1) and/or 5550(a)(2).
• Seeking transfer of listing to the Nasdaq Capital Market.
• Future capital raising activities to support operations and clinical trials for SIL204.

Key Dates

Recommendation

Keywords

Biotechnology, Oncology, RNA interference, RNAi, KRAS mutations, SIL204, LODER, Pancreatic cancer, Nasdaq listing, Reverse share split, Capital raise, SEC filing, Proxy statement, Corporate governance, Clinical trials